## BMY: Bristol-Myers Squibb Company - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -0.4% below STRENGTH zone (3.0-6.0%); PEG 2.26 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($52.07)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 2, Bearish: 0)

**1. What Does Wall Street Think About Bristol-Myers Squibb Company (BMY)?**
- Source: Insider Monkey | 20251230T050741 | Bullish | Relevance: 100%
- Bristol-Myers Squibb Company (BMY) received a Buy rating from Guggenheim with a $62.00 price target on December 22, 2025. The company also announced an agreement with the U.S. government to provide Eliquis for free to Medicaid and donate over seven tons of its active pharmaceutical ingredient, ensuring supply chain resilience and addressing key administration priorities. Additionally, the agreement includes direct-to-patient access for certain medications at discounted prices.

**2. Bristol Myers Squibb (BMY) Stock: Weekend News, Analyst Targets, Dividend Update, and What to Watch Before Mondayâ€™s Open**
- Source: ts2.tech | 20251228T202814 | Neutral | Relevance: 100%
- Bristol Myers Squibb (BMY) stock ended the week at $54.64, with investors weighing the company's defensive profile and dividend appeal against upcoming patent expirations. Recent news includes institutional activity, mixed analyst targets averaging around $53.93-$59.50, and key pipeline developments for Opdivo and neuroscience programs. The company also announced a 1.6% dividend increase and investors are watching policy implications, especially regarding the Eliquis agreement with the U.S. government, as they head into Monday's trading session and Q4 2025 earnings in February 2026.

**3. BMY vs AMGN: Which Biotech Stock Is More Resilient Now?**
- Source: Finviz | 20251230T132200 | Somewhat-Bullish | Relevance: 100%
- This article compares two biotech giants, Bristol Myers Squibb (BMY) and Amgen (AMGN), evaluating their growth portfolios, challenges, and valuation metrics. While BMY shows strong performance in its growth portfolio, it faces headwinds from its legacy drugs. AMGN boasts a diverse portfolio and promising pipeline candidates, making it a slightly better pick despite its higher valuation.

**4. Bristol Myers Squibb Company $BMY Shares Purchased by Fort Washington Investment Advisors Inc. OH**
- Source: MarketBeat | 20251230T120046 | Bullish | Relevance: 100%
- Fort Washington Investment Advisors Inc. OH increased its stake in Bristol Myers Squibb (BMY) by 3.3% in the third quarter, now owning 2,686,511 shares valued at $121.16 million. Other institutions also increased their holdings, with Norges Bank initiating a significant stake, bringing total institutional ownership to 76.41%. Analysts currently have a consensus "Hold" rating on BMY with a target price of $54.62.

**5. Ethic Inc. Raises Stock Holdings in Bristol Myers Squibb Company $BMY**
- Source: MarketBeat | 20251230T093455 | Somewhat-Bullish | Relevance: 100%
- Ethic Inc. significantly increased its stake in Bristol Myers Squibb Company by 100.4% in the third quarter, bringing its total holdings to 203,955 shares valued at approximately $9.20 million. This increase comes as Bristol Myers Squibb exceeded Q3 earnings estimates, issued strong FY2025 guidance, and raised its quarterly dividend to $0.63, reflecting a robust financial position and positive outlook despite a consensus "Hold" rating from analysts.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 5, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-15 | B of A Securiti | $61 | $52 | +17% |
| 2025-12-12 | Morgan Stanley | $37 | $36 | +3% |
| 2025-12-12 | Guggenheim | $62 | $0 | 0% |
| 2025-12-10 | Wells Fargo | $55 | $53 | +4% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-15 | B of A Securiti | up | Buy |
| 2025-12-12 | Morgan Stanley | main | Underweight |
| 2025-12-12 | Guggenheim | up | Buy |
| 2025-12-10 | Wells Fargo | main | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 2 ($0.00M) |
| Sells | 3 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 41.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 2 |

**Top Holders:**
- Vanguard Group Inc: 9.6% (+0.5%)
- Blackrock Inc.: 8.6% (+1.9%)
- JPMORGAN CHASE & CO: 8.5% (+65.8%)
- State Street Corpora: 4.7% (+2.0%)
- Charles Schwab Inves: 3.6% (+3.2%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Analyst target momentum: 5 raises (avg +11%) could attract flows.
- AI/machine learning initiatives could drive multiple expansion if executed.

### Fundamentals

PEG ratio 2.26 elevated, pricing in significant growth expectations. Quality metrics strong (ROE 34%). Balance sheet: $6.0B free cash flow. Revenue declining -8% YoY, concerning. Analyst sentiment positive (5 raises, avg +11%). Institutional flow bullish (7 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $110.4B |
| Beta | 0.30 |
| 52W Range | $42.52 - $63.33 |
| Short Interest | 1.7% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.26 |
| Forward P/E | 9.0 |
| Current P/E | 8.3 |
| YoY Growth | -8.3% |
| EPS Direction | STABLE |

### Technicals

MRS_10 weakening modestly (-0.8% over 5 days). Below STRENGTH zone by 3.4pp (needs >3.0% for momentum thesis). MRS_5 turning positive (0.2%) - potential reversal signal. Full SMA alignment bullish (above 20/50/200 SMAs). OFD pattern: +SLL (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -0.36% (CS: 49) | Neutral |
| RSI_14 | 65.4 | Neutral |
| MACD Histogram | -0.08 | Bearish |
| vs SMA20 | 1.026x | Above |
| vs SMA50 | 1.109x | Above |
| vs SMA200 | 1.116x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $54.23
- **Stop Loss:** $52.07 (4.0% risk)
- **Target:** $56.39 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 611
- **Position Value:** $33,134.53
- **Portfolio %:** 33.13%
- **Risk Dollars:** $1,320.00
- **Risk Per Trade:** 1.32%
- **Modifiers:** L1 110% | L2 120% | Combined 1.32x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (HIGH) | 1.10x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with balanced risk signals and moderate market participation. VIX at 14.33 indicates calm conditions, while positive yield curve (+59bps) and stable economic data support continued expansion. Year-end positioning and Fed uncertainty create near-term caution, but no systemic risks evident.*

### Earnings

**Next:** 2026-02-05 (Est: $1.65)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.52 | $1.63 | +7.6% |
| 2025Q2 | $1.10 | $1.46 | +32.6% |
| 2025Q1 | $1.50 | $1.80 | +19.9% |
| 2024Q4 | $1.47 | $1.67 | +13.8% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*